Organism: Homo sapiens
Gene: 38633_at
Selected probe(set): 211783_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 38633_at (211783_s_at) across 6674 perturbations tested by GENEVESTIGATOR:

Relative Expression (log2-ratio):-3.1306133
Number of Samples:3 / 3

Experimental	oncolytic herpes simplex virus study 2
	Human malignant peripheral nerve sheath tumor (S462) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours.
Control	mock infected peripheral nerve sheath tumor (S462) cell sample
	Human malignant peripheral nerve sheath tumor (S462) cells mock infected for 6 hours.

Relative Expression (log2-ratio):2.8550673
Number of Samples:2 / 2

Experimental	expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic)
	Metastatic tumor tissue samples obtained from patients with primary granulosa cell tumor of the ovary.
Control	expO ovary cancer study 1 (dysgerminoma; metastatic)
	Metastatic tumor tissue samples obtained from patients with primary dysgerminoma of the ovary.

Relative Expression (log2-ratio):-2.6267347
Number of Samples:4 / 2

Experimental	oxyphilic adenoma study 1
	Tumor tissue samples from the kidney of patients with oxyphilic adenoma (renal oncocytoma).
Control	normal kidney tissue (fetal)
	Normal fetal kidney tissue samples.

Relative Expression (log2-ratio):2.4632454
Number of Samples:3 / 2

Experimental	expO ovary cancer study 1 (endometrioid carcinoma; metastatic)
	Metastatic tumor tissue samples obtained from patients with primary endometrioid carcinoma of the ovary.
Control	expO ovary cancer study 1 (dysgerminoma; metastatic)
	Metastatic tumor tissue samples obtained from patients with primary dysgerminoma of the ovary.

Relative Expression (log2-ratio):-2.3851557
Number of Samples:8 / 17

Experimental	pediatric septic shock study 3 (infant; subclass A)
	Whole blood samples obtained from infants (1 month – 1 year) with septic shock subclass A. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. Two children did not survive. The subclass A was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients in subclass A (when all age groups were pooled) had a significantly higher illness severity level (PRISM III score = 20.5, intra-quartile range (IQR) 12.5 – 32.5), a greater degree of organ failure – maximum number of organ failures 3 (IQR 3 - 4), and a higher mortality rate, a significantly higher incidence of documented Gram-positive bacterial infection and were significantly younger compared with other subclasses.
Control	normal blood sample (infant)
	Whole blood samples from infants (1 month – 1 year). Children who had a recent febrile illness (within 2 weeks), who recently used anti-inflammatory medications (within 2 weeks) or who had any history of chronic or acute disease associated with inflammation were excluded from the study.

Relative Expression (log2-ratio):-2.350792
Number of Samples:4 / 18

Experimental	pediatric septic shock study 3 (toddler; subclass A)
	Whole blood samples obtained from toddlers (2 – 5 years) with septic shock subclass A. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. One child did not survive. The subclass A was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients in subclass A (when all age groups were pooled) had a significantly higher illness severity level (PRISM III score = 20.5, intra-quartile range (IQR) 12.5 – 32.5), a greater degree of organ failure – maximum number of organ failures 3 (IQR 3 - 4), and a higher mortality rate, a significantly higher incidence of documented Gram-positive bacterial infection and were significantly younger compared with other subclasses.
Control	normal blood sample (toddler)
	Whole blood samples from toddlers (2 – 5 years). Children who had a recent febrile illness (within 2 weeks), who recently used anti-inflammatory medications (within 2 weeks) or who had any history of chronic or acute disease associated with inflammation were excluded from the study.

Relative Expression (log2-ratio):-2.220314
Number of Samples:4 / 4

Experimental	dendritic cell study 6 (gardiquimod; RN486)
	Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.
Control	dendritic cell study 6 (CpG A; RN486)
	Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with CpG-A ODN2216 Class A (TLR9 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.

Relative Expression (log2-ratio):2.137786
Number of Samples:4 / 2

Experimental	glioma study 27 (glioblastoma, NOS)
	Primary tumor samples from resected brain tissues of patients with glioblastoma, NOS(WHO grade IV astrocytoma).
Control	glioma study 27 (pilocytic astrocytoma)
	Primary tumor samples from resected brain tissues of patients with pilocytic astrocytoma (WHO grade I astrocytoma).

Relative Expression (log2-ratio):2.1215382
Number of Samples:4 / 3

Experimental	nephroblastoma study 2
	Tumor tissue samples from the kidney of patients with Wilms’ tumor.
Control	normal kidney tissue (adult)
	Normal adult kidney tissue samples.

Relative Expression (log2-ratio):2.0682821
Number of Samples:2 / 64

Experimental	basal cell carcinoma study 2
	Primary tumor tissue from the skin of patients with basal cell carcinoma (BCC).
Control	normal skin tissue
	Normal skin samples from healthy donors.